Table 3. Trends in enrolment, sex, WHO clinical stage, CD4+ cell count, haemoglobin and data collection, FGH Nigeria Cohort, 2009–2013.
| 2009 | 2010 | 2011 | 2012 | 2013 | Combined | ||
| Cumulative enrollment, n | (n = 377) | (n = 936) | (n = 1192) | (n = 1230) | (n = 225) | (n = 3960) | P-valued |
| Clinic enrolment, n (%) | 377 | 1313 | 2505 | 3735 | 3960 | < 0.001 | |
| GBRH | 208 (55%) | 447 (48%) | 19 (2%) | 91 (7%) | 102 (45%) | 867 (22%) | |
| Kuta | 0 (0%) | 41 (4%) | 72 (6%) | 12 (1%) | 0 (0%) | 125 (3%) | |
| LGH | 92 (24%) | 157 (17%) | 117 (10%) | 85 (7%) | 56 (25%) | 507 (13%) | |
| SBSH | 77 (20%) | 265 (28%) | 245 (21%) | 256 (21%) | 67 (30%) | 910 (23%) | |
| UMYMH | 0 (0%) | 26 (3%) | 739 (62%) | 786 (64%) | 0 (0%) | 1551 (39%) | |
| Age (years), median (IQR) | 34 (27–40) | 32 (27–40) | 31 (26–39) | 32 (27–40) | 34 (29–40) | 32 (27–40) | 0.68 |
| Female, n (%) | 235 (62%) | 655 (70%) | 807 (68%) | 857 (70%) | 148 (66%) | 2702 (68%) | 0.33 |
| WHO clinical stage, n (%) | < 0.001 | ||||||
| I | 135 (37%) | 310 (35%) | 610 (55%) | 685 (62%) | 112 (55%) | 1852 (50%) | |
| II | 67 (19%) | 195 (22%) | 216 (20%) | 244 (22%) | 57 (28%) | 779 (21%) | |
| III | 140 (39%) | 354 (40%) | 257 (23%) | 160 (14%) | 29 (14%) | 940 (26%) | |
| IV | 20 (6%) | 29 (3%) | 21 (2%) | 24 (2%) | 4 (2%) | 98 (3%) | |
| CD4 count (cells/μL), median (IQR)a | 241 (112–389) | 246 (121–402) | 228 (113–384) | 222 (113–393) | 218 (95–354) | 230 (114–390) | 0.14 |
| Haemoglobin (g/dL), median (IQR)a | 10.3 (9.2–11.6) | 10.7 (9.4–12) | 10.7 (9.1–12) | 10.7 (9.5–11.9) | 10.4 (8.6–11.7) | 10.7 (9.3–11.9) | 0.26 |
| BMI (kg/m2), median (IQR) | 20.1 (18.3–22.3) | 20.6 (18.4–23.0) | 21.6 (19.1–24.3) | 20.8 (18.4–23.4) | 20.5 (17.6–22.5) | 20.8 (18.5–23.4) | < 0.001 |
| WHO clinical stage data collection, n (%)c | 362 (96%) | 888 (95%) | 1104 (93%) | 1113 (90%) | 202 (90%) | 3669 (93%) | < 0.001 |
| CD4 data collection, n (%)c | 344 (91%) | 839 (90%) | 863 (72%) | 1062 (86%) | 164 (73%) | 3272 (83%) | < 0.001 |
| Haemoglobin data collection, n (%)c | 250 (66%) | 545 (58%) | 559 (47%) | 623 (51%) | 41 (18%) | 2018 (51%) | < 0.001 |
| BMI data collection, n (%) | 354 (94%) | 748 (80%) | 730 (61%) | 563 (46%) | 53 (24%) | 2448 (62%) | < 0.001 |
| ART eligibility at enrolment, n (%) | < 0.001 | ||||||
| Eligible | 181 (48%) | 599 (64%) | 708 (59%) | 791 (64%) | 135 (60%) | 2414 (61%) | |
| Not eligible | 162 (43%) | 249 (27%) | 212 (18%) | 270 (22%) | 36 (16%) | 929 (23%) | |
| Indeterminate | 34 (9%) | 88 (9%) | 272 (23%) | 169 (14%) | 54 (24%) | 617 (16%) |
aCD4 count and haemoglobin are summarised using median (interquartile range).
bPercentages are computed using the number of patients with a non-missing value.
cCD4, haemoglobin, WHO clinical stage are collected at enrolment. Enrolment data are collected in a window of ± 90 days from date of enrolment.
dTo compare the distribution of study characteristics for participants by year, we employ Kruskal–Wallis tests. Similarly, we use a Spearman rank correlation test for continuous variables by year.